Kenvue upgraded by Piper Sandler with a new price target
$KVUE
Specialty Chemicals
Consumer Discretionary
Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/29/2025 | $15.00 | Buy → Hold | Canaccord Genuity |
| 9/26/2025 | $22.00 | Neutral → Buy | Rothschild & Co Redburn |
| 4/10/2025 | $23.50 | Neutral | Redburn Atlantic |
| 3/24/2025 | $25.00 | In-line | Evercore ISI |
| 1/6/2025 | $21.00 → $26.00 | Neutral → Overweight | Piper Sandler |
| 12/12/2024 | $25.00 → $24.00 | Buy → Hold | Deutsche Bank |
| 9/24/2024 | $27.00 | Buy | Jefferies |
| 9/24/2024 | $24.00 | Outperform → Sector Perform | RBC Capital Mkts |
3 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
4 - Kenvue Inc. (0001944048) (Issuer)
Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk
Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K
Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation
Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K
Net Sales (3.5)%; Organic Sales1 (4.4)% Diluted EPS was $0.21; Adjusted Diluted EPS1 was $0.28 Affirms Outlook for FY'25 Kirk Perry Named Permanent Chief Executive Officer and Company Announced Additional Key Leadership Appointments Kenvue Inc. (NYSE:KVUE) today announced financial results for the third quarter ended September 28, 2025. "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance," said Kirk Perry, Chief Executive Officer. "Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvue's performance and unlock th
Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po
425 - Kenvue Inc. (0001944048) (Subject)
SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)
425 - Kenvue Inc. (0001944048) (Subject)
Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00
Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00
Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50
Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K
Net Sales (3.5)%; Organic Sales1 (4.4)% Diluted EPS was $0.21; Adjusted Diluted EPS1 was $0.28 Affirms Outlook for FY'25 Kirk Perry Named Permanent Chief Executive Officer and Company Announced Additional Key Leadership Appointments Kenvue Inc. (NYSE:KVUE) today announced financial results for the third quarter ended September 28, 2025. "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance," said Kirk Perry, Chief Executive Officer. "Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvue's performance and unlock th
Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)
SC 13G/A - Kenvue Inc. (0001944048) (Subject)